Andy Porter

Andy was one of the founders of Elasmogen and as CTO manages the company’s extensive patent portfolio and IP strategy. He also holds a number of Non-Exec positions in Life Science and other businesses in Scotland. Andy is part-time Professor of Medical Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen. Since 2005 he has been a Fellow of the Royal Society of Edinburgh and until recently was VP Business. Andy has worked with academics and companies across the world, developing biologics to a range of diagnostic and therapeutic targets including: oncology, inflammation, CNS disease and most recently Covid-19. Andy is a graduate of St Andrews University.